524 related articles for article (PubMed ID: 15687366)
1. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
2. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
3. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW
Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791
[TBL] [Abstract][Full Text] [Related]
4. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
5. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
6. Down syndrome, drug metabolism and chromosome 21.
Taub JW; Ge Y
Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
9. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
10. Origins of leukaemia in children with Down syndrome.
Hitzler JK; Zipursky A
Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.
Ge Y; Jensen TL; Matherly LH; Taub JW
Blood; 2003 Feb; 101(4):1551-7. PubMed ID: 12393509
[TBL] [Abstract][Full Text] [Related]
12. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
13. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
Momparler RL; Eliopoulos N; Bovenzi V; Létourneau S; Greenbaum M; Cournoyer D
Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
[TBL] [Abstract][Full Text] [Related]
15. A leukemogenic twist for GATA1.
Look AT
Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
[No Abstract] [Full Text] [Related]
16. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
18. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
20. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
